<DOC>
	<DOCNO>NCT00003402</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness peripheral stem cell transplantation plus combination chemotherapy treat patient low-grade non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Plus Combination Chemotherapy Treating Patients With Low-Grade Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate complete partial response rate treatment peripheral blood stem cell support high dose carmustine melphalan follow consolidation therapy dexamethasone/cyclophosphamide/etoposide/cisplatin ( DCEP ) dexamethasone , paclitaxel , cisplatin patient poor prognosis low grade non-Hodgkin 's lymphoma chronic lymphocytic leukemia great 12 month prior standard therapy . II . Evaluate incidence early death ( less 60 day posttransplant ) comparison historical experience patient population . III . Evaluate toxicity posttransplantation chemotherapy DCEP dexamethasone , paclitaxel , cisplatin patient . OUTLINE : Patients receive carmustine IV 2 hour day -2 melphalan IV day -1 follow peripheral blood stem cell infusion day 0 . At 3 month 9 month completion autologous transplantation , patient receive cyclophosphamide , etoposide , cisplatin continuous IV infusion 4 day plus dexamethasone orally every day 4 day . At 6 12 month completion autologous transplantation , patient receive dexamethasone orally every day 4 day , paclitaxel continuous IV infusion 6 hour day 2 , cisplatin continuous IV infusion 24 hour day 3 . PROJECTED ACCRUAL : There 12-35 patient accrue study 1-2.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm low grade follicular lymphoma , mantle cell lymphoma , chronic lymphocytic leukemia great 12 month prior standard therapy Follicular lymphoma Must poor prognosis disease define follow : Any nodal extranodal tumor mass diameter 7 cm Involvement least 3 nodal site , diameter great 3 cm Systemic symptom Substantial splenic involvement great 5 cm leave costal margin Serous effusion ( ascites , pleural pericardial effusion ) Orbital epidural involvement Ureteral compression Leukemia presentation ( least 500/microliter ) Increased LDH level Greater 20 % bone marrow involvement Mantle cell lymphoma No mantle zone morphology Chronic lymphocytic leukemia Must either anemia ( hemoglobin le 10 g/dL ) , thrombocytopenia ( less 100,000/mm3 ) , cytogenetic abnormality include +12 11q , elevate LDH level , label index least 2 % , systemic symptom , hepatosplenomegaly No active CNS disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 70 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : At least 4,000/g CD34+ peripheral blood stem cell available See Disease Characteristics Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal No active chronic hepatitis liver cirrhosis Renal : Creatinine great 2.0 mg/dL Cardiovascular : Left ventricular ejection fraction least 50 % Pulmonary : FEV1 , FVC , DLCO least 50 % predict Other : HIV negative No active infection require intravenous antibiotic Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Prior corticosteroid allow Radiotherapy : At least 4 week since prior local radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>